ROCKWELL MEDICAL, INC. Payments to Acquire Productive Assets
ROCKWELL MEDICAL, INC. (RMTI) reported Payments to Acquire Productive Assets of $1.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-08-13
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for the quarter ending 2026-06-30 was $617.00K, a 276.22% increase year-over-year.
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for the quarter ending 2026-03-31 was $425.00K, a 574.60% increase year-over-year.
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for the quarter ending 2025-12-31 was $86.00K, a 78.23% decline year-over-year.
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for the quarter ending 2025-09-30 was $229.00K, a 19.90% increase year-over-year.
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for fiscal 2025 was $542.00K, a 46.39% decline from fiscal 2024.
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for fiscal 2024 was $1.01M, a 255.99% increase from fiscal 2023.
- ROCKWELL MEDICAL, INC. payments to acquire productive assets for fiscal 2023 was $284.00K.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 9 month as first filed | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $617.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.04M 10-Q · filed 2026-08-13 | $1.13M derived: sum of 3 quarters · filed 2026-08-13 | $1.36M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $425.00K 10-Q · filed 2026-05-07 | $511.00K derived: sum of 2 quarters · filed 2026-05-07 | $740.00K derived: sum of 3 quarters · filed 2026-05-07 | $904.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $315.00K derived: sum of 2 quarters · filed 2026-03-26 | $479.00K derived: sum of 3 quarters · filed 2026-08-13 | $542.00K 10-K · filed 2026-03-26 | |
| 2025-09-30 | $229.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $393.00K derived: sum of 2 quarters · filed 2026-08-13 | $456.00K 10-Q · filed 2025-11-12 | $851.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $227.00K 10-Q · filed 2026-08-13 | $622.00K derived: sum of 3 quarters · filed 2026-08-13 | $813.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $63.00K 10-Q · filed 2026-05-07 | $458.00K derived: sum of 2 quarters · filed 2026-05-07 | $649.00K derived: sum of 3 quarters · filed 2026-05-07 | $935.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $395.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $586.00K derived: sum of 2 quarters · filed 2026-03-26 | $872.00K derived: sum of 3 quarters · filed 2026-03-26 | $1.01M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $477.00K derived: sum of 2 quarters · filed 2025-11-12 | $616.00K 10-Q · filed 2025-11-12 | $659.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $425.00K 10-Q · filed 2025-08-14 | $468.00K derived: sum of 3 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $139.00K 10-Q · filed 2025-05-12 | $182.00K derived: sum of 2 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $284.00K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $241.00K 10-Q · filed 2024-11-12 | $12.36M 10-Q · filed 2023-11-14 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |